51 - 100 employees
11 - 25 engineers
$10m - $25m funding
Series c

Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis (, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The IsoLight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies. IsoPlexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring. IsoPlexis provides a strong level of customer focus. We pride ourselves with a high level of integrity, energy and sense of urgency to “make things happen”.

Engineering at IsoPlexis

Tech stack

Working at IsoPlexis

Perks & benefits
  • Free Food

    Pizza Wednesdays and Happy Hour Fridays!

  • Company Retreats

    Off site learning at Water's Edge Resort & Spa, Westbrook, CT

Our Team by the Numbers

External Links

Interested in this company?
Skip straight to final-round interviews by applying through Triplebyte.